Johnson & Johnson/Janssen COVID-19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia - Update for Clinicians on Early Detection and Treatment

You may participate in this COCA Call via Zoom.

This COCA Call will present the latest evidence on cerebral venous sinus thrombosis (CVST) with thrombocytopenia associated with the administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers will discuss what is known about CVST, the importance of early detection, and updated vaccine recommendations.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends. The slide set will be available under "Call Materials" on the COCA Call webpage the day of the call. Continuing Education (CE) will not be provided for this call.  Advanced registration is not required.  Closed-captioning will not be available during today’s webinar. A transcript and closed-captioned video will be posted to the COCA Call webpage located at as soon as possible after today’s live session. 

Date: Thursday, April 15, 2021
Time: 2:00 pm - 3:00 pm (ET) 

A few minutes before the webinar starts, please click on the Zoom link below to join:

Or iPhone one-tap : 
US: +16692545252,,1614336614#,,,,*160026# 
or +16468287666,,1614336614#,,,,*160026#

Or Telephone: Dial (for higher quality, dial a number based on your current location): 
US +1 669 254 5252 or
+1 646 828 7666 or
+1 551 285 1373 or
+1 669 216 1590

Webinar ID: 161 433 6614
International numbers available

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation
  2. Discuss CDC's role in the topic covered during the presentation
  3. Describe the topic's implications for clinicians
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers


Sara Oliver, MD
LCDR, U.S. Public Health Service
Co-lead, Advisory Committee for  Immunization Practices COVID-19 Vaccines Work Group
COVID-19 Response
Centers for Disease Control and Prevention

Tom Shimabukuro, MD, MPH, MBA
CAPT, U.S. Public Health Service
Vaccine Safety Team Lead
COVID-19 Response
Centers for Disease Control and Prevention

The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at